Press Releases

Gift Guide for Showing Why Every Mom is Special

ATLANTA, GA / ACCESSWIRE / May 9, 2024 / Sunday, May 12th, is Mother's Day. Whether it is pampering mom, choosing a special gift, or creating a unique experience or meal, Mother's Day is about honoring everything moms do for the family all year long. Lindsay Roberts, founder of TheGiftInsider.com, gives some suggestions for making celebrations on this special day for mom, grandma and all the special mothers everywhere... (continue reading...)

PHILADELPHIA, PA / ACCESSWIRE / May 9, 2024 / abrdn Life Sciences Investors (HQL) and abrdn Healthcare Investors (HQH), (collectively, the "Funds") each, a closed-end management investment company, announced today its Board of Trustees (each a "Board" and collectively, the "Boards") have approved an increase in each Fund's respective annualized distribution rate on NAV from 10% to 12%.

Notably, HQH and HQL had previously announced distribution increases in February 2024,... (continue reading...)

ISELIN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Provident Financial Services, Inc. (NYSE: PFS) (the “Company”), the holding company for Provident Bank (the “Bank”), today announced the pricing of its offering of $225 million of its 9.00% fixed-to-floating rate subordinated notes due 2034 (the “Notes”) in a registered public offering (the “Offering”). The Notes will initially bear interest at 9.00% per annum, with interest payable semiannually in... (continue reading...)

MILPITAS, Calif.--(BUSINESS WIRE)-- SMART Global Holdings, Inc. (“SGH” or the “Company”) (NASDAQ: SGH) today announced that it will host an Analyst Day in New York City on Tuesday, July 16, 2024, at 10 a.m. Eastern Time. Live and on-demand webcasts of the event will be available on the SGH Investor Relations website for those unable to attend in person. Additional details, including registration instructions, will be provided closer to the event... (continue reading...)

30 month median overall survival (OS); median OS independent of patient CPS score

ORR 34% (CPS≥1); 48% (CPS≥20)

Phase 3 registrational trial planned to initiate in 2024

PRINCETON, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines,... (continue reading...)